FDA Recognises Potential to Address Unmet Need
MRM Health announced that its lead candidate MH002 received Fast Track designation by the U.S. Food and Drug Administration (FDA) for mild-to-moderate ulcerative colitis as of 30th April 2026.
This designation emphasises MH002's potential to address the serious condition of ulcerative colitis, which has high unmet medical needs. Fast Track status accelerates development and facilitates increased interactions with the FDA, streamlining the review process.
MRM Health describes MH002 as a rationally designed Live Biotherapeutic Product composed of a microbial consortium of six well-characterised commensal strains. It specifically targets mechanisms related to inflammatory bowel disease (IBD).
Phase 2a Trial Results and Next Steps
The Fast Track designation is supported by a Phase 2a clinical trial showing excellent safety and encouraging efficacy signals. MH002 demonstrated positive outcomes in mucosal healing, microbiome balance recovery, and clinical remission induction, with no observed adverse reactions.
MRM Health plans further evaluation of MH002 in a Phase 2b study called STARFISH-UC. This study will involve approximately 204 patients across Europe and the United States, with results expected in the fourth quarter of 2027.
Dr. Sam Possemiers, CEO of MRM Health, stated, "The FDA’s decision to grant Fast Track designation to MH002 recognises the potential of this promising Live Biotherapeutic Product to address the significant unmet need for innovative and more effective therapies for patients with ulcerative colitis."
MRM Health will present at Digestive Disease Week 2026 in Chicago, from 2nd to 5th May. CEO Dr. Sam Possemiers will lead a session on 5th May discussing MH002's initial clinical data and future trial design.
The FDA's Fast Track process is designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The goal is to get important drugs to patients earlier.
Products with Fast Track status may qualify for Accelerated Approval and Priority Review. Companies may submit completed sections of the New Drug Application (NDA) on a rolling basis.
Professor Geert D’Haens, MD, a gastroenterologist and investigator at Amsterdam UMC, observed that live biotherapeutic approaches open new avenues for treating immune-mediated diseases like ulcerative colitis. He noted, "While several treatments are available for UC, this is mostly the case for moderate-to-severe UC patients. Many patients still fail to achieve durable remission or require treatment escalation, underscoring the need for novel treatment options."
